Stock report · Delisted · Nasdaq
Arcellx Inc (ACLX)
115.07USD Delisted Final close · Apr 27, 2026
ACLX no longer trades. Arcellx was acquired by Gilead (GILD) on April 28, 2026.
All prices on this page are historical. The last trade was on April 27, 2026, at $115.07.
ACLX stock price history
Final trading statistics
- Final close
- $115.07
- Final trading day
- Apr 27, 2026
- Market cap at delisting
- $6.73B
- Shares outstanding
- 58.51M
- Final 52-week range
- $47.86 – $115.13
- Avg. volume (final 3 mo.)
- 2,380,082
- All-time high
- $115.10 · Apr 2026
- All-time low
- $7.21 · May 2022
- Return since IPO
- +584.9%
- Beta
- 0.25
- Book value / share
- $6.95
- Price / book
- 16.57
About Arcellx Inc
Arcellx, Inc. and its subsidiary developed immunotherapies in the U.S. for cancer and other incurable diseases. Its lead ddCAR candidate, anitocabtagene autoleucel, was in a phase 2 trial for relapsed or refractory multiple myeloma (rrMM).
ACLX-001, aimed at BCMA for rrMM, and ACLX-002, aimed at CD123 for relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), were in Phase 1. ACLX-004 was a preclinical candidate for AML and MDS, and the company also had solid tumor programs.
It partnered with Kite Pharma, Inc. to jointly develop and sell nito-cel and next-generation CAR-T therapies. Incorporated in 2014 and based in Redwood City, California, it was known as Encarta Therapeutics, Inc. until January 2016.
Gilead (GILD) acquired Arcellx on April 28, 2026, making it a subsidiary of Gilead Sciences, Inc. The stock last traded on April 27, 2026 at $115.07.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Redwood City, CA
- Employees
- 209
- IPO date
- February 4, 2022
- Delisted
- April 28, 2026
- SEC CIK
- 1786205
Arcellx financials before the delisting
The last 5 fiscal years Arcellx reported as a public company, fiscal year ending December.
ACLX revenue and net income
ACLX earnings per share
ACLX annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $22.29M | −$228.9M | −$4.07 |
| FY2024 | $107.94M | −$107.3M | −$2.00 |
| FY2023 | $110.32M | −$70.7M | −$1.47 |
| FY2022 | $17.91M | −$188.7M | −$5.32 |
| FY2021 | $0.00 | −$63.9M | −$41.12 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Arcellx stock FAQ
What happened to Arcellx stock?
Arcellx was acquired by Gilead (GILD) on April 28, 2026. The final close was $115.07 on April 27, 2026.
Can I still buy ACLX stock?
No. ACLX is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on April 28, 2026.
What was the last price of ACLX?
ACLX last closed at $115.07 on April 27, 2026, which valued the company at about $6.73B.
How did Arcellx do in its last full fiscal year?
In fiscal 2025, its last full year as a public company, Arcellx reported revenue of $22.29M and net income of −$228.9M.
When did Arcellx go public?
Arcellx shares started trading on February 4, 2022.
ACLX no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.